塔格昔福治疗母细胞性浆细胞样树突状细胞肿瘤（BPDCN）：关于新出现数据的简要报告
Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data.
作者信息
Beziat Guillaume, Ysebaert Loïc
机构信息
Hematology Department, University Hospitals of Toulouse, IUC Toulouse-Oncopole, Toulouse, France.
University Toulouse-3 Paul Sabatier, Toulouse, France.
出版信息
Onco Targets Ther. 2020 Jun 9;13:5199-5205. doi: 10.2147/OTT.S228342. eCollection 2020.
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare myeloid malignancy, for which conventional chemotherapy has poor outcomes. CD123, the α-subunit of interleukin (IL)-3 receptor, is constantly overexpressed at the surface of tumoral cells. Tagraxofusp (or SL-401) is a recombinant cytotoxin which consists of human interleukin-3 fused to a truncated diphtheria toxin. It is currently the only novel therapy with a prospective evaluation of efficacy and safety in the treatment of BPDCN and is also the only one to achieve FDA approval. In this short review, the results of tagraxofusp are summarized and perspectives of its use in BPDCN and in other malignancies are discussed. The safety profile is also summarized, since capillary leak syndrome is the main toxic effect of the drug, along with more common toxicities including an increase in transaminases and thrombocytopenia.
摘要
母细胞样浆细胞样树突状细胞肿瘤（BPDCN）是一种罕见的髓系恶性肿瘤，传统化疗对此疗效不佳。白细胞介素（IL）-3受体的α亚基CD123在肿瘤细胞表面持续过度表达。塔格昔单抗（或SL-401）是一种重组细胞毒素，由与人白细胞介素-3融合的截短白喉毒素组成。它是目前唯一一种对治疗BPDCN的疗效和安全性进行前瞻性评估的新型疗法，也是唯一获得美国食品药品监督管理局（FDA）批准的疗法。在这篇简短的综述中，总结了塔格昔单抗的治疗结果，并讨论了其在BPDCN和其他恶性肿瘤中的应用前景。还总结了其安全性概况，因为毛细血管渗漏综合征是该药物的主要毒性作用，同时还包括转氨酶升高和血小板减少等更常见的毒性反应。
相似文献
1
Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data.塔格昔福治疗母细胞性浆细胞样树突状细胞肿瘤（BPDCN）：关于新出现数据的简要报告
Onco Targets Ther. 2020 Jun 9;13:5199-5205. doi: 10.2147/OTT.S228342. eCollection 2020.
2
Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.塔拉唑单抗治疗原始浆细胞样树突状细胞瘤。
Expert Rev Anticancer Ther. 2020 Jul;20(7):543-550. doi: 10.1080/14737140.2020.1776120. Epub 2020 Jun 24.
3
Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm.塔格拉索夫，一种用于治疗母细胞样浆细胞样树突状细胞瘤的新型靶向CD123的细胞毒素。
Drugs Today (Barc). 2019 Dec;55(12):735-742. doi: 10.1358/dot.2019.55.12.3058917.
4
Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope.塔拉唑索夫联合抗 CD123 治疗原始浆细胞样树突状细胞瘤：新希望。
Minerva Med. 2020 Oct;111(5):467-477. doi: 10.23736/S0026-4806.20.07018-4. Epub 2020 Sep 21.
5
Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm.Tagraxofusp，首个靶向 CD123 的治疗药物，也是首个用于治疗原始浆细胞样树突状细胞瘤的靶向药物。
Expert Rev Clin Pharmacol. 2019 Oct;12(10):941-946. doi: 10.1080/17512433.2019.1662297. Epub 2019 Oct 1.
6
Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature.塔拉唑素，一种首创的靶向 CD123 的药物：文献的五年上市后综合回顾。
Cancer. 2024 Jul 1;130(13):2260-2271. doi: 10.1002/cncr.35315. Epub 2024 Apr 15.
7
Blastic Plasmacytoid Dendritic Cell Neoplasm.母细胞性浆细胞样树突状细胞肿瘤
J Natl Compr Canc Netw. 2023 May;21(5):515-521. doi: 10.6004/jnccn.2023.7026.
8
Relapse of tagraxofusp treated blastic plasmacytoid dendritic cell neoplasm with loss of CD123 expression.接受他格拉索夫治疗的母细胞性浆细胞样树突状细胞肿瘤复发并伴有CD123表达缺失。
J Hematop. 2022 Mar;15(1):35-39. doi: 10.1007/s12308-021-00479-z. Epub 2021 Dec 2.
9
Targeting CD123 in BPDCN: an emerging field.针对 BPDCN 中的 CD123：一个新兴领域。
Expert Rev Hematol. 2021 Nov;14(11):993-1004. doi: 10.1080/17474086.2021.1988848. Epub 2021 Oct 29.
10
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.塔拉唑滨治疗原始浆细胞样树突状细胞瘤。
N Engl J Med. 2019 Apr 25;380(17):1628-1637. doi: 10.1056/NEJMoa1815105.
引用本文的文献
1
Some Examples of Bacterial Toxins as Tools.一些细菌毒素作为工具的例子。
Toxins (Basel). 2024 Apr 23;16(5):202. doi: 10.3390/toxins16050202.
2
Multiple Genomic Alterations, Including a Novel Fusion Gene, in a Treatment-Refractory Blastic Plasmacytoid Dendritic-Cell Neoplasm: A Case Report and Literature Review.治疗抵抗性原始浆细胞样树突状细胞瘤中的多种基因组改变，包括一种新的融合基因：病例报告及文献复习。
Int J Mol Sci. 2023 Dec 25;25(1):305. doi: 10.3390/ijms25010305.
3
Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview.母细胞性浆细胞样树突状细胞肿瘤（BPDCN）：临床特征、组织病理学及治疗概述
Hematol Rep. 2023 Dec 8;15(4):696-706. doi: 10.3390/hematolrep15040070.
4
Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021.美国食品药品监督管理局生物药批准情况的趋势与展望：2015年至2021年综述
Biomedicines. 2022 Sep 19;10(9):2325. doi: 10.3390/biomedicines10092325.
5
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.Tagraxofusp 治疗原始浆细胞样树突状细胞瘤患者的长期获益。
J Clin Oncol. 2022 Sep 10;40(26):3032-3036. doi: 10.1200/JCO.22.00034. Epub 2022 Jul 12.
6
Phenazine derivatives attenuate the stemness of breast cancer cells through triggering ferroptosis.吩嗪衍生物通过触发铁死亡来减弱乳腺癌细胞的干性。
Cell Mol Life Sci. 2022 Jun 11;79(7):360. doi: 10.1007/s00018-022-04384-1.
7
Differences and similarities between cancer and somatic stem cells: therapeutic implications.癌症与体干细胞之间的差异和相似性：治疗意义。
Stem Cell Res Ther. 2020 Nov 18;11(1):489. doi: 10.1186/s13287-020-02018-6.
本文引用的文献
1
Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm.骨髓造血细胞移植治疗原始浆细胞样树突状细胞瘤。
Hematol Oncol Clin North Am. 2020 Jun;34(3):621-629. doi: 10.1016/j.hoc.2020.01.009. Epub 2020 Mar 17.
2
Blastic Plasmacytoid Dendritic Cell Neoplasm: The European Perspective.原始滤泡性淋巴瘤：欧洲观点。
Hematol Oncol Clin North Am. 2020 Jun;34(3):613-620. doi: 10.1016/j.hoc.2020.01.012. Epub 2020 Apr 4.
3
Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm.反应性和肿瘤性浆细胞样树突状细胞的免疫表型特征有助于建立 10 色流式细胞术面板，用于初始检查和浆母细胞样树突状细胞瘤残留疾病的评估。
Haematologica. 2021 Apr 1;106(4):1047-1055. doi: 10.3324/haematol.2020.247569.
4
New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm.在原始浆细胞样树突细胞肿瘤的遗传学和靶向治疗方面的新视角。
Crit Rev Oncol Hematol. 2020 May;149:102928. doi: 10.1016/j.critrevonc.2020.102928. Epub 2020 Mar 2.
5
FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.FDA 批准概要：Tagraxofusp-erzs 用于治疗原始浆细胞样树突细胞肿瘤。
Clin Cancer Res. 2020 Feb 1;26(3):532-536. doi: 10.1158/1078-0432.CCR-19-2329. Epub 2019 Sep 23.
6
CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies.CD123作为血液系统恶性肿瘤治疗的一个治疗靶点。
Cancers (Basel). 2019 Sep 12;11(9):1358. doi: 10.3390/cancers11091358.
7
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.DNA 甲基转移酶抑制克服了 CD123 靶向治疗耐药性的二氢嘧啶酶途径缺陷。
J Clin Invest. 2019 Nov 1;129(11):5005-5019. doi: 10.1172/JCI128571.
8
Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm.TCF4 和 CD123 的双重表达对于原始浆细胞样树突状细胞瘤具有高度的敏感性和特异性。
Am J Surg Pathol. 2019 Oct;43(10):1429-1437. doi: 10.1097/PAS.0000000000001316.
9
Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark.多中心分析浆母细胞样树突状细胞瘤的结果为靶向前治疗提供了基准。
Blood. 2019 Aug 22;134(8):678-687. doi: 10.1182/blood.2019001144. Epub 2019 Jun 26.
10
Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects.母细胞性浆细胞样树突状细胞肿瘤：现状与展望
Cancers (Basel). 2019 Apr 28;11(5):595. doi: 10.3390/cancers11050595.
Zotero 插件